"10.1371_journal.pone.0057479","plos one","2013-02-28T00:00:00Z","Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Yukiko Okuyama-Nishida; Chifumi Moriyama; Tetsuya Wakabayashi; Eriko Tanaka; Atsushi Muto; Tetsuo Kojima; Takehisa Kitazawa; Kazutaka Yoshihashi; Aya Harada; Miho Funaki; Kenta Haraya; Tatsuhiko Tachibana; Sachiyo Suzuki; Keiko Esaki; Yoshiaki Nabuchi; Kunihiro Hattori","Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan","Provided direction and guidance: YN. Provided the hypothesis of the bispecific antibody, directed and organized the program: K. Hattori. Conceived and designed the experiments: TI T. Kojima T. Kitazawa. Performed the experiments: ZS TI TS YON CM TW ET AM KY AH MF K. Haraya TT SS KE. Wrote the paper: ZS TI.","All authors are employees of Chugai Pharmaceutical Co., Ltd. which is conducting the clinical study of hBS910 (ACE910). TS, T. Kojima and KH are inventors of the patents and patent applications which claim FVIII-mimetic bispecific antibodies to FIXa and FX. ZS, TI, TS, YON, CM, AM, T. Kojima, T. Kitazawa and KY are inventors of the patent application which claims hBS910, the investigational drug. These do not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","02","Zenjiro Sampei","ZS",19,TRUE,2,12,NA,2,TRUE,FALSE,TRUE,1,"16",FALSE
